食卫局局长认可复星/BioNTech新冠疫苗在香港作紧急使用
食物及卫生局局长今日(25日)根据《预防及控制疾病(使用疫苗)规例》(第599K章),认可复星医药/德国药厂BioNTech的新冠疫苖(即Comirnaty COVID-19 mRNA Vaccine(BNT162b2)Concentrate for Dispersion for Injection)在香港作紧急使用。
根据疫苗供应商提供的资料,准备供港的首批约100万剂复星医药/德国药厂BioNTech疫苗已经完成生产程序,并在进行安全和品质测试。视乎有关测试顺利完成和通过,有关疫苗预计可於2月下旬由德国运抵香港。政府会在接收到有关疫苗并完成必须的质检程序後,尽快启动由政府主导的全港性疫苗接种计划。政府会同时继续积极跟进其余本港已采购疫苗的紧急使用批核和供应时间表,并做好相关疫苗接种安排的筹备工作。政府亦会继续按照疫苗采购策略,预先采购其他能够符合安全、效能及质素要求包括仍在研发阶段的新冠疫苗,以确保全港市民能有不同疫苗及足够供应可供接种。
根据《规例》,食物及卫生局局长可在参考2019冠状病毒病疫苗顾问专家委员会的意见後,认可符合安全、效能及质素要求的新冠疫苗在香港於紧急情况下作指明目的,基本上指由政府推行的疫苗接种计划。顾问专家委员会已向食物及卫生局局长提交建议,认为在现时疫情情况下,认可使用复星医药/德国药厂BioNTech的新冠疫苗作为预防2019冠状病毒病的效益大於风险。
顾问专家委员会亦注意到一些海外国家,就接种复星医药/德国药厂BioNTech疫苗後收到的怀疑不良情况的报告。根据有关当局公布的资料,疫苗一些常见的副作用,例如发烧或恶心,可能会对一些自身已有严重病患、身体尤其虚弱的人士有影响。卫生署已因应顾问专家委员会建议,要求疫苗供应商提供相关资料。卫生防护中心辖下的联合科学委员会会审视相关资料,以助厘定接种该疫苗的优先组别须注意事项。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.